10-Q: Aadi Bioscience Reports First Quarter 2024 Financial Results, Provides Clinical Trial Updates

Aadi Bioscience reported a net loss of $18.3 million for the first quarter of 2024, with product sales of $5.4 million, and provided updates on its clinical trials.

Summary

• Aadi Bioscience reported a net loss of $18.3 million for the first quarter of 2024, compared to a net loss of $15.2 million for the same period in 2023.
• Product sales for the quarter were $5.4 million, a decrease from $5.9 million in the first quarter of 2023, due to distributor ordering patterns and fewer new patient initiations.
• The company's operating expenses totaled $24.9 million, including $10.6 million in selling, general and administrative expenses and $13.6 million in research and development expenses.
• Research and development expenses increased by $2.6 million compared to the same period last year, primarily due to increased clinical development expenses related to the PRECISION1 trial and clinical drug product manufacturing.
• As of March 31, 2024, Aadi Bioscience had $88.3 million in cash, cash equivalents, and short-term investments.
• Management believes the company's current cash, cash equivalents and short-term investments will provide sufficient funds to meet its obligations for at least twelve months from the filing date of this report.
• The company has fully enrolled the PRECISION1 trial and expects to report the two-thirds interim analysis in the third quarter of 2024, with the overall response rate analysis of such two-thirds cohort based on independent radiological review with a minimum of six months of follow-up for all patients.
• Aadi Bioscience amended its agreement with Fresenius Kabi to extend the term to July 31, 2024, and modify terms related to pricing, forecasting, and minimum purchase commitments.
• The company terminated its collaboration and supply agreement with Mirati Therapeutics to prioritize other clinical programs.

Sentiment

Score: 5

Explanation: The document presents mixed signals. While the company has a solid cash position and is progressing with clinical trials, the increased net loss and decreased product sales are concerning. The termination of the Mirati collaboration also adds uncertainty. Overall, the sentiment is neutral to slightly negative.

Positives

• The company has sufficient funds to meet its obligations for at least twelve months from the filing date of this report.
• The PRECISION1 trial is fully enrolled and expected to be completed by the end of 2024.
• The company has amended its agreement with Fresenius Kabi, securing supply through July 31, 2024.

Negatives

• The company experienced an increased net loss of $18.3 million in Q1 2024 compared to $15.2 million in Q1 2023.
• Product sales decreased to $5.4 million in Q1 2024 from $5.9 million in Q1 2023.
• The company terminated its collaboration with Mirati Therapeutics, which may impact future development plans.

Risks

• The company's future success is highly dependent on the commercial success of FYARRO and the development of additional indications.
• The company may not be able to obtain regulatory approval for FYARRO in additional indications or for other product candidates.
• The company relies on third-party manufacturers for the production of FYARRO, which could lead to supply disruptions.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's stock price is volatile and may be subject to significant fluctuations.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms or at all.

Future Outlook

Management believes the company's current cash, cash equivalents and short-term investments will provide sufficient funds to enable the company to meet its obligations for at least twelve months from the filing date of this report. The company expects to report the two-thirds interim analysis of the PRECISION1 trial in the third quarter of 2024, with the overall response rate analysis of such two-thirds cohort based on independent radiological review with a minimum of six months of follow-up for all patients. The trial is expected to be completed by the end of 2024, with results anticipated in early 2025.

Management Comments

• Management believes the company's current cash, cash equivalents and short-term investments will provide sufficient funds to enable the company to meet its obligations for at least twelve months from the filing date of this report.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on precision therapies for cancers with alterations in the mTOR pathway. The termination of the Mirati collaboration reflects a strategic shift to prioritize other clinical programs. The company's focus on rare cancers and specific genetic alterations aligns with the industry trend towards personalized medicine.

Comparison to Industry Standards

• Aadi Bioscience's Q1 2024 results show a decrease in product sales compared to the same period last year, which may be a concern for investors looking for consistent revenue growth. This contrasts with some other commercial-stage biopharma companies that have shown more robust sales growth.
• The increase in R&D expenses is typical for companies in this sector as they advance clinical trials, but the magnitude of the increase should be monitored for its impact on cash burn.
• The company's cash position of $88.3 million is relatively strong, providing a runway into the fourth quarter of 2025, which is comparable to other companies of similar size and stage.
• The termination of the Mirati collaboration is a strategic decision that may be viewed positively if it allows the company to focus on more promising programs, but it also highlights the risks associated with clinical development and the need for careful resource allocation.
• The full enrollment of the PRECISION1 trial is a positive milestone, but the timeline for results (early 2025) is longer than some investors may prefer, and the company will need to manage expectations carefully.

Legal Proceedings

• The company is involved in an ongoing arbitration process with EOC Pharma (Hong Kong) Limited related to the termination of a license agreement.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased product sales.
• Employees may be affected by the restructuring of commercial, medical affairs, and corporate support functions.
• Customers may be affected by changes in the supply chain and product availability.
• Suppliers may be affected by changes in the company's manufacturing and supply agreements.

Next Steps

• The company expects to report the two-thirds interim analysis of the PRECISION1 trial in the third quarter of 2024.
• The company expects to complete the PRECISION1 trial by the end of 2024, with results anticipated in early 2025.
• The company will continue to advance its clinical programs for FYARRO in EEC and NETs.

Key Dates

Keywords

Aadi Bioscience, FYARRO, PEComa, mTOR pathway, clinical trials, PRECISION1, financial results, biopharmaceutical, oncology, drug development